Ask AI
See Activity Collection
ProCE Banner Activity

From Data to Decisions: Integrating TROP2 ADC Evidence Into NSCLC Care

Clinical Thought

As TROP2-directed antibody–drug conjugates (ADCs) reshape the treatment landscape for advanced non-small-cell lung cancer (NSCLC), healthcare professionals face important questions about treatment sequencing, patient selection, and toxicity management. In this commentary, experts examine emerging clinical evidence for datopotamab deruxtecan and sacituzumab tirumotecan, the potential role of predictive biomarkers, and opportunities to integrate ADCs into earlier treatment settings. They also discuss practical strategies for managing adverse events and highlight the importance of balancing efficacy, tolerability, and quality of life to optimize individualized patient care.

Released: November 03, 2026

Begin Activity

Share

Faculty

Christine M. Bestvina

Christine M. Bestvina, MD

Associate Professor of Medicine
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois
Joshua E. Reuss

Joshua E. Reuss, MD

Thoracic Medical Oncologist
Director of Thoracic Clinical Research
Associate Professor of Medicine
Georgetown Lombardi Comprehensive Cancer Center
Washington, DC

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck Sharp & Dohme LLC.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for medical oncologists, pulmonologists, and other healthcare professionals involved in the care of patients with advanced/metastatic NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the current and evolving role of TROP2-directed ADCs in advanced/metastatic NSCLC, including current evidence-based use of Dato-DXd and emerging investigational strategies across frontline, biomarker-enriched, and combination settings

  • Apply established biomarkers and patient-specific clinical factors to guide selection, sequencing, and clinical trial referral for TROP2-directed ADCs and ADC-based strategies in advanced/metastatic NSCLC

  • Appraise emerging global clinical trial evidence for TROP2-directed ADCs, including Dato-DXd, sac-TMT/MK-2870, ADC–immunotherapy combinations, ADC–EGFR TKI combinations, and biomarker-driven approaches

  • Implement multidisciplinary strategies to prevent, monitor, and manage TROP2 ADC–associated adverse events, including stomatitis/oral mucositis, ocular toxicity, nausea, myelosuppression, and ILD/pneumonitis

Financial Disclosures

Primary Author

Christine M. Bestvina, MD: advisor/consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Exelixis, Genentech, Jazz, Johnson & Johnson, Lilly, MBrace, Merck, Novartis, Pfizer, Rigel, Summit, Turning Point Therapeutics, Voronoi; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb.

Joshua E. Reuss, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, EMD Serono, Gilead, Guardant, Janssen, Lilly, Merck, Natera, Nuvation Bio, Pfizer, Regeneron, Roche Diagnostics, Summit; researcher (paid to institution): Amgen, Arcus, Duality Bio, Genentech/Roche, Genmab, Nuvalent, Onco-C4, Regeneron, Revolution Medicines, Sutro, Verastem.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.